The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332
Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.
There are currently 21 open trials.
In 108 locations
What is a Clinical Trial?
There are currently 21 open trials
- Evaluating patient-based treatment strategies for newly diagnosed myeloma patients (RADAR)
- Belantamab mafodotin in combination with bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-7)
- Belantamab mafodotin versus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-3)
- A clinical trial evaluating RO5126766 for the treatment of refractory myeloma patients
- Understanding bone pain in myeloma
- Belantamab mafodotin (GSK2857916) combinations for treatment of relapsed/refractory myeloma (DREAMM-6)
- A study evaluating the standard care of relapsed/refractory myeloma patients (LocoMMotion)
- CCS1477 for the treatment of relapsed/refractory myeloma patients
- Oxford pre-cancerous disorders study (OxPLoreD)
- A study evaluating S65487 for the treatment of relapsed/refractory myeloma patients
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Using diffusion weighted MRI to measure myeloma disease burden and bone loss (LOOMIS)
- Exercise in transplant eligible myeloma patients (PERCEPT)
- Venetoclax and dexamethasone in patients with relapsed or refractory myeloma (CANOVA)
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma patients (MUK twelve)
- CC-92480 in combination with dexamethasone in relapsed and refractory multiple myeloma
- AZD4573 in relapsed or refractory myeloma
- Observational evaluation of myeloma patients (PREAMBLE)
- CC-220 (iberdomide) as a monotherapy and in combination with other treatments
- Myeloma XII (ACCoRd)
Trial Title:
Evaluating patient-based treatment strategies for newly diagnosed myeloma patients (RADAR)
Treatments:
Lenalidomide (Revlimid)
Cyclophosphamide
Bortezomib (Velcade®)
Dexamethasone
Isatuximab
Autologous stem cell transplant
Myeloma stage:
Newly Diagnosed
Trial phase:
II, III
Summary:
A trial evaluating different treatment strategies for newly diagnosed myeloma patients.
During the trial, patients will be assigned treatments based on how well they respond to initial treatment and the genetic risk status (high or standard) of their myeloma.
Locations:
University College Hospital, London;
St James' Hospital, Leeds
Who can enter the study?:
Newly diagnosed myeloma patients who are eligible for high-dose therapy and stem cell transplantation (HDT-SCT).
What's involved?:
Patients will receive:
- Induction treatment: lenalidomide, cyclophosphamide, bortezomib and dexamethasone
- HDT-SCT
Following HDT-SCT patients will be assigned different treatment groups (A, B, C) depending on their genetic risk status and on how well the myeloma has responded to the initial treatment.
Treatment combinations following HDT-SCT will comprise of either isatuximab, bortezomib, cyclophosphamide, lenalidomide or dexamethasone.
Patients will be required to attend outpatient clinics for regular check-ups and tests.
Clinical Information
(for Medical Professionals):
A randomised, Phase 2/ 3 trial comparing treatment escalation and de-escalation strategies in transplant eligible, newly diagnosed myeloma patients. For more information, click here.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk